{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T19:42:45Z","timestamp":1787773365006,"version":"build-2784847793"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"2-3","license":[{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T00:00:00Z","timestamp":1666396800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pharmacogenomics J"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1038\/s41397-022-00295-3","type":"journal-article","created":{"date-parts":[[2022,10,22]],"date-time":"2022-10-22T13:05:16Z","timestamp":1666443916000},"page":"45-49","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":14,"title":["Meta-analysis of pharmacogenetic clinical decision support systems for the treatment of major depressive disorder"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4942-8556","authenticated-orcid":false,"given":"Valentin","family":"Skryabin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilya","family":"Rozochkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mikhail","family":"Zastrozhin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Volker","family":"Lauschke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Franck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evgeny","family":"Bryun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitry","family":"Sychev","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,10,22]]},"reference":[{"key":"295_CR1","doi-asserted-by":"publisher","first-page":"453","DOI":"10.3390\/pharmaceutics11090453","volume":"11","author":"S Vilches","year":"2019","unstructured":"Vilches S, Tuson M, Vieta E, \u00c1lvarez E, Espadaler J. Effectiveness of a pharmacogenetic tool at improving treatment efficacy in major depressive disorder: a meta-analysis of three clinical studies. Pharmaceutics. 2019;11:453. https:\/\/doi.org\/10.3390\/pharmaceutics11090453.","journal-title":"Pharmaceutics"},{"key":"295_CR2","doi-asserted-by":"publisher","first-page":"575540","DOI":"10.3389\/fphar.2020.575540","volume":"11","author":"RHN van Schaik","year":"2020","unstructured":"van Schaik RHN, M\u00fcller DJ, Serretti A, Ingelman-Sundberg M. Pharmacogenetics in psychiatry: an update on clinical usability. Front Pharm. 2020;11:575540. https:\/\/doi.org\/10.3389\/fphar.2020.575540.","journal-title":"Front Pharm"},{"key":"295_CR3","doi-asserted-by":"publisher","first-page":"559","DOI":"10.2217\/pgs-2019-0157","volume":"21","author":"L Brown","year":"2020","unstructured":"Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21:559\u201369. https:\/\/doi.org\/10.2217\/pgs-2019-0157.","journal-title":"Pharmacogenomics"},{"key":"295_CR4","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1038\/s41397-021-00249-1","volume":"21","author":"K Karamperis","year":"2021","unstructured":"Karamperis K, Koromina M, Papantoniou P, Skokou M, Kanellakis F, Mitropoulos K, et al. Economic evaluation in psychiatric pharmacogenomics: a systematic review. Pharmacogenomics J. 2021;21:533\u201341. https:\/\/doi.org\/10.1038\/s41397-021-00249-1.","journal-title":"Pharmacogenomics J"},{"key":"295_CR5","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1016\/j.psychres.2018.12.053","volume":"271","author":"HV Solomon","year":"2019","unstructured":"Solomon HV, Cates KW, Li KJ. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions? Psychiatry Res. 2019;271:604\u201313. https:\/\/doi.org\/10.1016\/j.psychres.2018.12.053.","journal-title":"Psychiatry Res"},{"key":"295_CR6","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1038\/s41746-020-0221-y","volume":"3","author":"RT Sutton","year":"2020","unstructured":"Sutton RT, Pincock D, Baumgart DC, Sadowski DC, Fedorak RN, Kroeker KI. An overview of clinical decision support systems: benefits, risks, and strategies for success. NPJ Digit Med 2020;3:17. https:\/\/doi.org\/10.1038\/s41746-020-0221-y.","journal-title":"NPJ Digit Med"},{"key":"295_CR7","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.3390\/pharmaceutics12121240","volume":"12","author":"KA Malsagova","year":"2020","unstructured":"Malsagova KA, Butkova TV, Kopylov AT, Izotov AA, Potoldykova NV, Enikeev DV, et al. Pharmacogenetic testing: A tool for personalized drug therapy optimization. Pharmaceutics. 2020;12:1240. https:\/\/doi.org\/10.3390\/pharmaceutics12121240.","journal-title":"Pharmaceutics"},{"key":"295_CR8","doi-asserted-by":"publisher","first-page":"e24","DOI":"10.2196\/medinform.8912","volume":"6","author":"S Khairat","year":"2018","unstructured":"Khairat S, Marc D, Crosby W, Al Sanousi A. Reasons for physicians not adopting clinical decision support systems: Critical analysis. JMIR Med Inf. 2018;6:e24. https:\/\/doi.org\/10.2196\/medinform.8912.","journal-title":"JMIR Med Inf"},{"key":"295_CR9","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1016\/S2215-0366(16)00017-1","volume":"3","author":"CA Bousman","year":"2016","unstructured":"Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016;3:585\u201390. https:\/\/doi.org\/10.1016\/S2215-0366(16)00017-1.","journal-title":"Lancet Psychiatry"},{"key":"295_CR10","doi-asserted-by":"publisher","first-page":"S412","DOI":"10.1093\/schbul\/sby018.1009","volume":"44","author":"D Mueller","year":"2018","unstructured":"Mueller D, Tiwari A, Zai C, Kennedy J. S222. Clinical utility of pharmacogenetic testing in schizophrenia treatment. Schizophr Bull 2018;44:S412. https:\/\/doi.org\/10.1093\/schbul\/sby018.1009.","journal-title":"Schizophr Bull"},{"key":"295_CR11","doi-asserted-by":"publisher","first-page":"S122","DOI":"10.1192\/j.eurpsy.2021.346","volume":"64","author":"A Kibitov","year":"2021","unstructured":"Kibitov A, Kiryanova E, Salnikova L, Zmeyeva E, Shmukler A, Kibitov A. The DRD2\/ANKK1 Taq1A polymorphism in CYP2D6 extensive metabolizers is associated with the severity of extrapyramidal side effects of haloperidol treatment in schizophrenia spectrum disorders patients. Eur Psychiatry 2021;64:S122\u2013S123. https:\/\/doi.org\/10.1192\/j.eurpsy.2021.346.","journal-title":"Eur Psychiatry"},{"key":"295_CR12","doi-asserted-by":"publisher","first-page":"294","DOI":"10.9740\/mhc.2018.11.294","volume":"8","author":"M Routhieaux","year":"2018","unstructured":"Routhieaux M, Keels J, Tillery EE. The use of pharmacogenetic testing in patients with schizophrenia or bipolar disorder: A systematic review. Ment Health Clin [Internet]. 2018;8:294\u2013302. https:\/\/doi.org\/10.9740\/mhc.2018.11.294.","journal-title":"Ment Health Clin [Internet]"},{"key":"295_CR13","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1186\/s13012-017-0644-2","volume":"12","author":"EG Liberati","year":"2017","unstructured":"Liberati EG, Ruggiero F, Galuppo L, Gorli M, Gonz\u00e1lez-Lorenzo M, Maraldi M, et al. What hinders the uptake of computerized decision support systems in hospitals? A qualitative study and framework for implementation. Implement Sci. 2017;12:113. https:\/\/doi.org\/10.1186\/s13012-017-0644-2.","journal-title":"Implement Sci"},{"key":"295_CR14","doi-asserted-by":"publisher","first-page":"1191","DOI":"10.2217\/pgs-2020-0066","volume":"21","author":"D Roosan","year":"2020","unstructured":"Roosan D, Hwang A, Law AV, Chok J, Roosan MR. The inclusion of health data standards in the implementation of pharmacogenomics systems: a scoping review. Pharmacogenomics. 2020;21:1191\u2013202. https:\/\/doi.org\/10.2217\/pgs-2020-0066.","journal-title":"Pharmacogenomics"},{"key":"295_CR15","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1002\/cpt.1651","volume":"107","author":"MV Relling","year":"2020","unstructured":"Relling MV, Klein TE, Gammal RS, Whirl-Carrillo M, Hoffman JM, Caudle KE. The clinical pharmacogenetics implementation consortium: 10 years later. Clin Pharm Ther. 2020;107:171\u20135. https:\/\/doi.org\/10.1002\/cpt.1651.","journal-title":"Clin Pharm Ther"},{"key":"295_CR16","doi-asserted-by":"publisher","first-page":"209","DOI":"10.2174\/1389200215666140130124910","volume":"15","author":"KE Caudle","year":"2014","unstructured":"Caudle KE, Klein TE, Hoffman JM, Muller DJ, Whirl-Carrillo M, Gong L, et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr Drug Metab. 2014;15:209\u201317. https:\/\/doi.org\/10.2174\/1389200215666140130124910.","journal-title":"Curr Drug Metab"},{"key":"295_CR17","doi-asserted-by":"publisher","first-page":"2368","DOI":"10.1016\/j.xphs.2017.04.051","volume":"106","author":"ME Klein","year":"2017","unstructured":"Klein ME, Parvez MM, Shin JG. Clinical implementation of pharmacogenomics for personalized precision medicine: barriers and solutions. J Pharm Sci. 2017;106:2368\u201379. https:\/\/doi.org\/10.1016\/j.xphs.2017.04.051.","journal-title":"J Pharm Sci"},{"key":"295_CR18","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1208\/s12248-017-0161-x","volume":"20","author":"VM Lauschke","year":"2017","unstructured":"Lauschke VM, Milani L, Ingelman-Sundberg M. Pharmacogenomic biomarkers for improved drug therapy\u2014recent progress and future developments. AAPS J. 2017;20:4. https:\/\/doi.org\/10.1208\/s12248-017-0161-x.","journal-title":"AAPS J"},{"key":"295_CR19","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1080\/03602532.2021.1909613","volume":"53","author":"LE Russell","year":"2021","unstructured":"Russell LE, Zhou Y, Almousa AA, Sodhi JK, Nwabufo CK, Lauschke VM. Pharmacogenomics in the era of next generation sequencing - from byte to bedside. Drug Metab Rev. 2021;53:253\u201378. https:\/\/doi.org\/10.1080\/03602532.2021.1909613.","journal-title":"Drug Metab Rev"},{"key":"295_CR20","doi-asserted-by":"publisher","first-page":"917","DOI":"10.1038\/sj.ejhg.5201867","volume":"15","author":"M Kroese","year":"2007","unstructured":"Kroese M, Zimmern RL, Farndon P, Stewart F, Whittaker J. How can genetic tests be evaluated for clinical use? Experience of the UK Genetic Testing Network. Eur J Hum Genet. 2007;15:917\u201321. https:\/\/doi.org\/10.1038\/sj.ejhg.5201867.","journal-title":"Eur J Hum Genet"},{"key":"295_CR21","doi-asserted-by":"publisher","first-page":"1224","DOI":"10.1038\/gim.2017.181","volume":"21","author":"NJ Keeling","year":"2019","unstructured":"Keeling NJ, Rosenthal MM, West-Strum D, Patel AS, Haidar CE, Hoffman JM. Preemptive pharmacogenetic testing: exploring the knowledge and perspectives of US payers. Genet Med. 2019;21:1224\u201332. https:\/\/doi.org\/10.1038\/gim.2017.181.","journal-title":"Genet Med"},{"key":"295_CR22","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1002\/cpt.1912","volume":"108","author":"RJ Marrero","year":"2020","unstructured":"Marrero RJ, Cicali EJ, Arwood MJ, Eddy E, DeRemer D, Ramnaraign BH, et al. How to transition from single-gene pharmacogenetic testing to preemptive panel-based testing: A tutorial. Clin Pharm Ther. 2020;108:557\u201365. https:\/\/doi.org\/10.1002\/cpt.1912.","journal-title":"Clin Pharm Ther"},{"key":"295_CR23","doi-asserted-by":"publisher","first-page":"940","DOI":"10.1002\/phar.1786","volume":"36","author":"JK Hicks","year":"2016","unstructured":"Hicks JK, Stowe D, Willner MA, Wai M, Daly T, Gordon SM, et al. Implementation of clinical pharmacogenomics within a large health system: from electronic health record decision support to consultation services. Pharmacotherapy. 2016;36:940\u20138. https:\/\/doi.org\/10.1002\/phar.1786.","journal-title":"Pharmacotherapy"},{"key":"295_CR24","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1002\/cpt.602","volume":"101","author":"CH van der Wouden","year":"2017","unstructured":"van der Wouden CH, Cambon-Thomsen A, Cecchin E, Cheung KC, D\u00e1vila-Fajardo CL, Deneer VH, et al. Implementing pharmacogenomics in Europe: design and implementation strategy of the ubiquitous pharmacogenomics consortium. Clin Pharm Ther. 2017;101:341\u201358. https:\/\/doi.org\/10.1002\/cpt.602.","journal-title":"Clin Pharm Ther"},{"key":"295_CR25","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1038\/s41436-018-0337-5","volume":"21","author":"S Reisberg","year":"2019","unstructured":"Reisberg S, Krebs K, Lepamets M, Kals M, M\u00e4gi R, Metsalu K, et al. Translating genotype data of 44,000 biobank participants into clinical pharmacogenetic recommendations: challenges and solutions. Genet Med. 2019;21:1345\u201354. https:\/\/doi.org\/10.1038\/s41436-018-0337-5.","journal-title":"Genet Med"},{"key":"295_CR26","doi-asserted-by":"publisher","first-page":"628","DOI":"10.1038\/s41586-021-04103-z","volume":"599","author":"JD Backman","year":"2021","unstructured":"Backman JD, Li AH, Marcketta A, Sun D, Mbatchou J, Kessler MD, et al. Exome sequencing and analysis of 454,787 UK Biobank participants. Nature. 2021;599:628\u201334. https:\/\/doi.org\/10.1038\/s41586-021-04103-z.","journal-title":"Nature"},{"key":"295_CR27","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1016\/j.jpsychires.2019.01.003","volume":"111","author":"JF Greden","year":"2019","unstructured":"Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:59\u201367. https:\/\/doi.org\/10.1016\/j.jpsychires.2019.01.003.","journal-title":"J Psychiatr Res"},{"key":"295_CR28","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.jpsychires.2017.09.024","volume":"96","author":"P Bradley","year":"2018","unstructured":"Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:100\u20137. https:\/\/doi.org\/10.1016\/j.jpsychires.2017.09.024.","journal-title":"J Psychiatr Res"},{"key":"295_CR29","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1097\/FPC.0b013e3283649b9a","volume":"23","author":"DK Hall-Flavin","year":"2013","unstructured":"Hall-Flavin DK, Winner JG, Allen JD, Carhart JM, Proctor B, Snyder KA, et al. Utility of integrated pharmacogenomic testing to support the treatment of major depressive disorder in a psychiatric outpatient setting. Pharmacogenet Genomics. 2013;23:535\u201348. https:\/\/doi.org\/10.1097\/FPC.0b013e3283649b9a.","journal-title":"Pharmacogenet Genomics"},{"key":"295_CR30","doi-asserted-by":"publisher","DOI":"10.1186\/s12888-017-1412-1","volume":"17","author":"V P\u00e9rez","year":"2017","unstructured":"P\u00e9rez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, S\u00e1ez-Navarro C, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017;17:250. https:\/\/doi.org\/10.1186\/s12888-017-1412-1.","journal-title":"BMC Psychiatry"},{"key":"295_CR31","doi-asserted-by":"publisher","first-page":"150","DOI":"10.9758\/cpn.2015.13.2.150","volume":"13","author":"AB Singh","year":"2015","unstructured":"Singh AB. Improved antidepressant remission in major depression via a pharmacokinetic pathway polygene pharmacogenetic report. Clin Psychopharmacol Neurosci. 2015;13:150\u20136. https:\/\/doi.org\/10.9758\/cpn.2015.13.2.150.","journal-title":"Clin Psychopharmacol Neurosci"},{"key":"295_CR32","doi-asserted-by":"publisher","first-page":"37","DOI":"10.2217\/pgs-2018-0142","volume":"20","author":"CA Bousman","year":"2019","unstructured":"Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20:37\u201347. https:\/\/doi.org\/10.2217\/pgs-2018-0142.","journal-title":"Pharmacogenomics"},{"key":"295_CR33","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1159\/000492332","volume":"5","author":"K Yoshida","year":"2020","unstructured":"Yoshida K, M\u00fcller DJ. Pharmacogenetics of antipsychotic drug treatment: Update and clinical implications. Mol Neuropsychiatry. 2020;5:1\u201326. https:\/\/doi.org\/10.1159\/000492332.","journal-title":"Mol Neuropsychiatry"}],"container-title":["The Pharmacogenomics Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00295-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00295-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,26]],"date-time":"2023-04-26T09:05:58Z","timestamp":1682499958000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41397-022-00295-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,22]]},"references-count":33,"journal-issue":{"issue":"2-3","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["295"],"URL":"https:\/\/doi.org\/10.1038\/s41397-022-00295-3","relation":{},"ISSN":["1470-269X","1473-1150"],"issn-type":[{"value":"1470-269X","type":"print"},{"value":"1473-1150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,22]]},"assertion":[{"value":"6 September 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 October 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 October 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 October 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"VML is co is CEO and shareholder of HepaPredict AB, co-founder and shareholder of PersoMedix AB and discloses consultancy work for Enginzyme AB.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}